Literature DB >> 16026875

Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice.

Wolfgang Eicheler1, Mechthild Krause, Franziska Hessel, Daniel Zips, Michael Baumann.   

Abstract

BACKGROUND AND
PURPOSE: Preclinical and clinical data indicate that high pretherapeutic EGFR expression is associated with poor local tumour control, possibly caused by a high repopulation rate of clonogenic cells during radiotherapy in these tumours. Previous data reported from our laboratory showed a correlation between EGFR expression and acceleration of repopulation in poorly differentiated FaDu human squamous cell carcinoma (SCC) during fractionated irradiation. To test whether this is a general phenomenon, two further SCC were investigated in the present study. PATIENTS AND METHODS: GL and UT-SCC-14, two moderately well differentiated and keratinising hSCC, were grown as xenografts in nude mice. Functional data on the repopulation kinetics during fractionated irradiation for these tumour models have been previously determined. The expression of EGFR during fractionation was analysed by immunohistochemistry. Endpoints were the membrane-staining score and the proportion of EGFR-positive cells (EGFR labelling index).
RESULTS: Different kinetics of EGFR expression during fractionated RT were found. In UT-SCC-14, EGFR staining score and labelling index increased significantly during radiotherapy. In GL SCC, the EGFR expression was unchanged. Both tumours are characterized by a small but significant repopulation rate during radiotherapy.
CONCLUSIONS: The expression of EGFR may change significantly during fractionated irradiation. No clear correlation between EGFR expression and the repopulation kinetics of clonogenic tumour cells during fractionated irradiation was found. The changes in EGFR expression during irradiation warrant further investigation on their prognostic implications and on their importance for therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026875     DOI: 10.1016/j.radonc.2005.06.033

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

Review 1.  Radiation oncology in the era of precision medicine.

Authors:  Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld
Journal:  Nat Rev Cancer       Date:  2016-03-18       Impact factor: 60.716

2.  Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer.

Authors:  George D Wilson; Thomas G Wilson; Alaa Hanna; Mohamad Dabjan; Katie Buelow; John Torma; Brian Marples; Sandra Galoforo
Journal:  Clin Transl Radiat Oncol       Date:  2020-11-08

3.  Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts.

Authors:  Kristin Gurtner; Nadja Ebert; Dorothee Pfitzmann; Wolfgang Eicheler; Daniel Zips; Michael Baumann; Mechthild Krause
Journal:  Radiat Oncol       Date:  2014-12-02       Impact factor: 3.481

4.  Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).

Authors:  Alessandra Curioni-Fontecedro; Jean Yannis Perentes; Hans Gelpke; Alexandros Xyrafas; Hasna Bouchaab; Nicolas Mach; Oscar Matzinger; Nina Stojcheva; Martin Frueh; Walter Weder; Richard Cathomas; Piera Gargiulo; Lukas Bubendorf; Miklos Pless; Daniel Betticher; Solange Peters
Journal:  Br J Cancer       Date:  2019-04-16       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.